Big pharma will enter the cannabis sector ‘sooner than we thought’, Althea chief executive Josh Fegan has predicted, as he outlined the company’s growth potential and its ‘sprint’ for profitability.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

He told Cannabiz Althea should turn its first profit in FY22 — despite a A$15m loss in FY21 — and said its dual recreational and medicinal strategy would ensure sustained growth, provide ‘payback’ for shareholders and an attractive proposition for future investors.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...